diabetic retinopathy
Conditions
Interventions
Case series:Nil
Sponsors
First Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: healthy person Type 2 diabetes diagnoses according to the World Health Organization diagnostic criteria. DPN diagnoses according to Diabetes Care diagnostic criteria, including the nerve conduction(NC) tests abnormalities, neuropathy symptoms, signs. ;Inclusion criteria: healthy person Type 2 diabetes diagnoses according to the World Health Organization diagnostic criteria. DPN diagnoses according to Diabetes Care diagnostic criteria, including the nerve conduction(NC) tests abnormalities, neuropathy symptoms, signs.
Exclusion criteria
Exclusion criteria: 1. Type 1 diabetes; 2. glaucoma, severe vision loss or severe infection in both eyes; 3. There is a serious lens opacity or vitreous hemorrhage, such as cataracts; 4. have received anti-angiogenic drugs such as bevacizumab, ranibizumab and other treatment; 5. have undergone vitrectomy; 6. Patients with uncontrolled high blood pressure (HTN); 7. Patients with systemic infection, a history of cancer, severe cardiovascular and cerebrovascular diseases, rheumatic heart disease, chronic obstructive pulmonary disease and autoimmune diseases, including patients with rheumatoid arthritis or systemic lupus erythematosus; 8. severe liver and kidney dysfunction; 9. peritoneal dialysis or hemodialysis patients; 10. suffering from hepatitis B, hepatitis C, AIDS and other infectious diseases; 11. Gestational diabetes or diabetes with pregnancy.;Exclusion criteria: 1. Type 1 diabetes; 2. glaucoma, severe vision loss or severe infection in both eyes; 3. There is a serious lens opacity or vitreous hemorrhage, such as cataracts; 4. have received anti-angiogenic drugs such as bevacizumab, ranibizumab and other treatment; 5. have undergone vitrectomy; 6. Patients with uncontrolled high blood pressure (HTN); 7. Patients with systemic infection, a history of cancer, severe cardiovascular and cerebrovascular diseases, rheumatic heart disease, chronic obstructive pulmonary disease and autoimmune diseases, including patients with rheumatoid arthritis or systemic lupus erythematosus; 8. severe liver and kidney dysfunction; 9. peritoneal dialysis or hemodialysis patients; 10. suffering from hepatitis B, hepatitis C, AIDS and other infectious diseases; 11. Gestational diabetes or diabetes with pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Semaphorin3G;Diabetic retinopathy;;Semaphorin3G;Diabetic retinopathy; | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c;fasting C-peptide;Basic information of patients (height, weight, age);systolic pressure;diastolic pressure;diabetic duration;previous medical illness;Fasting plasma glucose;total cholesterol;triglyceride;Low density lipoprotein;high density lipoprotein;creatinine;urea nitrogen;glutamic-pyruvic transaminase;glutamic oxalacetic transaminase;;HbA1c;fasting C-peptide;Basic information of patients (height, weight, age);systolic pressure;diastolic pressure;diabetic duration;previous medical illness;Fasting plasma glucose;total cholesterol;triglyceride;Low density lipoprotein;high density lipoprotein;creatinine;urea nitrogen;glutamic-pyruvic transaminase;glutamic oxalacetic transaminase; | — |
Countries
China
Contacts
Public ContactZhang Huijuan, Bi Huili;Zhang Huijuan, Bi Huili ;
First Affiliated Hospital of Harbin Medical University;First Affiliated Hospital of Harbin Medical University
Outcome results
None listed